Pharmacokinetic and pharmacodynamic study of lenograstim for hematopoietic stem cell mobilization: a prospective randomized study for optimal apheresis-Reference-Cited by-同舟云学术

Pharmacokinetic and pharmacodynamic study of lenograstim for hematopoietic stem cell mobilization: a prospective randomized study for optimal apheresis

Published:2019-03-29 Issue:5 Volume:59 Page:1781-1788
ISSN:0041-1132
Container-title:Transfusion
language:en
Short-container-title:Transfusion

Author:

Kang Jihoon¹²,Hong Jung Yong¹,Yoon Dok Hyun¹,Kim Jeong Eun¹,Kim Kyu‐pyo¹,Kim Shin¹,Lee Kyoung Min¹,Park Jung Sun¹,Lee Ji Sung³,Suh Cheolwon¹

Affiliation:

1. Department of OncologyAsan Medical Center, University of Ulsan College of Medicine Seoul South Korea

2. Division of Hematology/Oncology, Department of Internal MedicineKangbuk Samsung Hospital, Sungkyunkwan University School of Medicine Seoul South Korea

3. Clinical Research Center, Asan Institute for Life Sciences, Asan Medical Center Seoul South Korea

Publisher

Wiley

Subject

Hematology,Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/trf.15265

Reference28 articles.

1. Hematologic recovery after autologous PBPC transplantation: importance of the number of postthaw CD34+ cells

2. Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations

3. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)

4. Minimal number of circulating CD34+ cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation

5. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients;Tricot G;Blood,1995